Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale, Dorr LLP and Skrine and Bär & Karrer advised The Tecan Group on the deal, while Schiff Hardin LLP represented Paramit Corporation....
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Amplitude Healthcare Corporation on the deal while Paul Hastings represented Jasper Therapeutics. Amplitude Healthcare Corporation (Nasdaq: AMHC), a special...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer...
You must be a Standard 1 Year member to access this content.
